FDA approves Entyvio, an injection to treat adult patients with moderate to severe ulcerative colitis and Crohn's disease.

BMS and AbbVie receive FDA breakthrough therapy designation for elotuzumab, an investigational humanized monoclonal antibody for multiple myeloma.

Novartis settles its litigation with the US subsidiary of Sun Pharma regarding Gleevec.

Meissner moves into its new headquarters in Camarillo, California.

FDA issues complete response letter for Novartis' RLX030 for acute heart failure.

Ascend Laboratories and Masters Pharmaceuticals cited in seizure of $11 million in unapproved drugs.

Hospira has recalled one lot of labetalol hydrochloride injection, USP, due to visible particulates.

AstraZeneca rejects Pfizer's final offer of $118 billion for a proposed merger of the two companies.

SGS makes two senior appointments at its new GMP/GLP laboratory in Carson, California.

EMA opens registration for it's sixth annual workshop on pediatric drug research and development.

FDA and EMA release a draft joint proposal on the development of new drugs to treat Gaucher disease in children.

Boehringer Ingelheim announced that it is working on a program to make clinical trial data and other related documents more widely accessible for approved products and drug-development programs that have been terminated.

EMA and ECHA sign agreement to share information and work together on risk assessments.

Hillary Clinton will deliver a keynote address at the 2014 BIO International Convention in San Diego.

New manufacturing capacity at the Le Mans, France facility is being used to scale up antibody drug conjugates.

Santen will purchase Merck's ophthalmology products business in Japan and key markets in Europe and Asia Pacific.

AstraZeneca will collaborate with the Medical Research Council Laboratory of Molecular Biology to fund a range of pre-clinical research projects.

Draft guidance addresses the use of clinical pharmacology studies to determine biosimilarity of biologics.

FDA clarifies stability data recommendations for abbreviated new drug applications.

Garvey's vial-drying system and pressure-less accumulator reduces drying time and decreases the risk of vial damage.

Eurofins Scientific will acquire ViraCor-IBT Laboratories for $255 million.

KBI Biopharma acquires Merck's microbial process development and manufacturing operations in Colorado.

Shire expands rare disease portfolio with acquisition of Lumena Pharmaceuticals.

AstraZeneca's Epanova is the first FDA-approved prescription omega-3 in free fatty acid form.

The Fogarty International Center, a component of the US NIH, calls for a focus on noncommunicable diseases and implementing science in low-resource settings.

A multi-institutional effort will fight pediatric leukemia and neuroblastoma.

FDA releases draft guidance on the development of drugs to treat hospital-acquired bacterial pneumonia (HABP) and ventilator-associated bacterial pneumonia.

The Pediatric Clinical Research Group initiative expands to include pediatric research sites.